(Bispecific) Antibodies in Cancer Patients
NCT05119257 · Status: AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2024-05-08
Summary
The aim of this project is to provide (bispecific) antibodies to individual patients with advanced solid and hematological malignancies without any available approved treatment options.
Conditions
Interventions
- BIOLOGICAL
-
Bispecific antibodies (bsAB)
BsAbs equipped with a target-specificity directed to a TAA and an effector-specificity for an activating receptor on T cells, such as CD3 or CD28, are applied intravenously in repeated cycles until disease progression or dose limiting toxicity.
Sponsors & Collaborators
-
University Hospital Tuebingen
lead OTHER
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
Countries
- Germany
Study Locations
More Related Trials
-
A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors
NCT06540066 ·Status: TERMINATED ·Phase: PHASE1
-
A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors
NCT02324257 ·Status: COMPLETED ·Phase: PHASE1
-
Immunization With 8 Peptides Mixed With CpG 7909 or Montanide ISA51 in Patients With Metastatic Cutaneous Melanoma
NCT00145158 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Immunotherapy of HLA-A2 Positive Stage III/IV Melanoma Patients
NCT00112229 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma
NCT01211262 ·Status: COMPLETED ·Phase: PHASE1
-
Monoclonal Antibody With or Without gp100 Peptides Plus Montanide ISA-51 in Treating Patients With Stage IV Melanoma
NCT00077532 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluating The Antitumor Activity Of MEDI-522 With Or Without Dacarbazine In Patients With Metastatic Melanoma
NCT00066196 ·Status: COMPLETED ·Phase: PHASE2
-
Immunization of HLA-A201 Patients With Metastatic Melanoma Using a Combination of Immunodominant Peptides From Three Melanoma Antigens, MART-1, GP100 and Tyrosinase
NCT00001685 ·Status: COMPLETED ·Phase: PHASE2
-
Vaccination of Metastatic Breast Cancer Patients With a CD80-modified Allogeneic Cancer Cell Line (KS2422)
NCT01127074 ·Status: COMPLETED ·Phase: PHASE1
-
Immunotherapy of Stage III/IV Melanoma Patients
NCT00112242 ·Status: COMPLETED ·Phase: PHASE1
-
Survivin Peptide Vaccination for Patients With Advanced Melanoma, Pancreatic, Colon and Cervical Cancer
NCT00108875 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery
NCT00025181 ·Status: COMPLETED ·Phase: PHASE1
-
RFT-5-dgA in Patients With Metastatic Melanoma
NCT00314093 ·Status: COMPLETED ·Phase: PHASE2
-
Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors
NCT06635785 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Immunotherapy of Cancer Using Donor Lymphocytes Labelled With In-vitro Bispecific Antibodies.
NCT00149019 ·Status: WITHDRAWN ·Phase: PHASE2
-
A First in Man Study of MABp1 in Patients With Advanced Cancers
NCT01021072 ·Status: COMPLETED ·Phase: PHASE1
-
Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors
NCT05103631 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Evaluation of a Multi-phosphopeptide Vaccine Plus PolyICLC in Participants With High Risk and Advanced Malignancies
NCT01846143 ·Status: COMPLETED ·Phase: PHASE1
-
Safety Study of 188Re-PTI-6D2 in Patients With Metastatic Melanoma
NCT00399113 ·Status: COMPLETED ·Phase: PHASE1
-
Multiepitope Peptide Vaccination in Melanoma
NCT00153569 ·Status: UNKNOWN ·Phase: PHASE2
-
Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Melanoma or Brain Tumors
NCT00002754 ·Status: COMPLETED ·Phase: PHASE1
-
A Study With ABL103 in Subjects With Advanced or Metastatic Solid Tumors
NCT06126666 ·Status: RECRUITING ·Phase: PHASE1
-
Integrated Discovery of New Immuno-Molecular Actionable Biomarkers for Tumors With Immune-suppressed Environment
NCT03706625 ·Status: COMPLETED
-
Treated T Cells Followed by a Stem Cell Transplant in Treating Patients With Multiple Myeloma
NCT00938626 ·Status: COMPLETED ·Phase: PHASE1
-
MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma
NCT07029776 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2